{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:12:22Z","timestamp":1782256342829,"version":"3.54.5"},"update-to":[{"DOI":"10.1002\/14651858.cd000459.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000}}],"reference-count":288,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd000459.pub3","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T22:12:34Z","timestamp":1517955154000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Antipsychotic reduction and\/or cessation and antipsychotics as specific treatments for tardive dyskinesia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Hanna","family":"Bergman","sequence":"first","affiliation":[{"name":"Cochrane; Cochrane Response; St Albans House 57-59 Haymarket London UK SW1Y 4QX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rathbone","sequence":"additional","affiliation":[{"name":"Bond University; Faculty of Health Sciences and Medicine; Robina Gold Coast Queensland Australia 4229"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Agarwal","sequence":"additional","affiliation":[{"name":"North Essex Partnership University NHS Foundation Trust; General Adult Psychiatry; The Lakes Mental Health Unit Turner Road Colchester Essex UK CO4 5JL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Soares-Weiser","sequence":"additional","affiliation":[{"name":"Cochrane; Cochrane Editorial Unit; St Albans House, 57 - 59 Haymarket London UK SW1Y 4QX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"key":"10.1002\/14651858.CD000459.pub3-BIB0001|cit1","first-page":"S165","article-title":"Risperidone for severe tardive dyskinesia: one year follow up study","volume":"5","author":"Bai","year":"2002","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00004850-200503000-00003","article-title":"Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study","volume":"20","author":"Bai","year":"2005","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.4088\/JCP.v64n1110","article-title":"Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study","volume":"64","author":"Bai","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0004|cit4","unstructured":"Pai YM Yu SC Lin CC Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA 2002"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0005|cit5","unstructured":"Pai YM Yu SC Lin CC Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA 2001"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0008|cit6","unstructured":"Bai YM Tardive dyskinesia and cognitive function clinicaltrials.gov\/ct2\/show\/record\/NCT00926965"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Bai YM Ping LY Lin CC Wang YC Liou YJ Wu BJ Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind, controlled study 8th World Congress of Psychiatry; 2005 Sep 10-15; Cairo, Egypt 2005","DOI":"10.1016\/S0924-977X(05)80979-4"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD000459.pub3-BIB0006|cit8","first-page":"S473","article-title":"Comparative effects of atypical antipsychotic on tardive dyskinesia and neurocognition: a 24-week randomized, single-blind, controlled study","volume":"15","author":"Bai","year":"2005","journal-title":"European Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"295","DOI":"10.4088\/JCP.09m05793yel","article-title":"Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia","volume":"72","author":"Caroff","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Miller DD Caroff SN Davis SM Rosenheck RA McEvoy JP Saltz BL Extrapyramidal side-effects of antipsychotics in a randomised trial British Journal of Psychiatry 2008 279 88","DOI":"10.1192\/bjp.bp.108.050088"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0011|cit11","doi-asserted-by":"crossref","unstructured":"Miller DD McEvoy JP Davis SM Caroff SN Saltz BL Chakos MH Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial Schizophrenia Research 2005 33 43","DOI":"10.1016\/j.schres.2005.07.034"},{"issue":"9","key":"10.1002\/14651858.CD000459.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.4088\/JCP.09m05155yel","article-title":"A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia","volume":"71","author":"Chan","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0013|cit13","unstructured":"NCT00621998 Risperidone and olanzapine for the schizophrenic patients with neuroleptic-induced tardive dyskinesia www.clinicaltrials.gov 2008"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0014|cit14","unstructured":"Chouinard G Arnott W An antidyskinetic effect of risperidone 9th World Congress of Psychiatry 1993 22"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients","volume":"13","author":"Chouinard","year":"1993","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD000459.pub3-BIB0018|cit16","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1097\/00004714-199502001-00007","article-title":"Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study","volume":"15","author":"Chouinard","year":"1995","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0016|cit17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00002826-199202001-00514","article-title":"Antidyskinetic effect of risperidone in chronic schizophrenic patients","volume":"15 (Suppl 1 Pt","author":"Chouinard","year":"1992","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0017|cit18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/0006-3223(92)90579-O","article-title":"The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients","volume":"31","author":"Chouinard","year":"1992","journal-title":"Biol Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004850-198704000-00008","article-title":"The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime","volume":"2","author":"Cookson","year":"1987","journal-title":"International Clinical Psychopharmacology"},{"issue":"5","key":"10.1002\/14651858.CD000459.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4088\/JCP.v65n0516","article-title":"A single-blind, randomized trial comparing quetiapine and haloperidol in the treatment of tardive dyskinesia","volume":"65","author":"Emsley","year":"2004","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0021|cit21","unstructured":"Emsley RA Turner J Schronen J Botha K Smit R Oosthuizen PP Quetiapine: greater improvements in tardive dyskinesia versus haloperidol 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, USA 2004"},{"issue":"5-6","key":"10.1002\/14651858.CD000459.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0920-9964(90)90016-Z","article-title":"A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia","volume":"3","author":"Glazer","year":"1990","journal-title":"Schizophrenia Research"},{"issue":"8","key":"10.1002\/14651858.CD000459.pub3-BIB0023|cit23","first-page":"4","article-title":"Molindone and haloperidol in tardive dyskinesia","volume":"46","author":"Glazer","year":"1985","journal-title":"Journal of Clinical Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD000459.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/archpsyc.1983.01790070083010","article-title":"Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates","volume":"40","author":"Kane","year":"1983","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1001\/archpsyc.1972.01750250086012","article-title":"Treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate","volume":"27","author":"Kazamatsuri","year":"1972","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","article-title":"Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine","volume":"130","author":"Kazamatsuri","year":"1973","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0924-977X(91)90008-I","article-title":"Zuclopenthixol, a combined dopamine D1\/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia","volume":"1","author":"Lublin","year":"1991","journal-title":"European Neuropsychopharmacology"},{"issue":"9, Suppl B","key":"10.1002\/14651858.CD000459.pub3-BIB0028|cit28","first-page":"102","article-title":"Clozapine in tardive dyskinsia: observations from human and animal model studies","volume":"55","author":"Tamminga","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/0006-3223(85)90006-X","article-title":"Tardive dyskinesia: relation to computer-tomographic, endocrine, and psychopatholgical variables","volume":"20","author":"Albus","year":"1985","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0030|cit30","first-page":"9","article-title":"An uncontrolled study with thiopropazate in the treatment of persistent dyskinesia","volume":"13","author":"Ananth","year":"1977","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00176839","article-title":"Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia","volume":"94","author":"Andersson","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0006-3223(97)00257-6","article-title":"Differential effect of haloperidol and clozapine on plasma homovanillic acid in elderly schizophrenic patients with or without tardive dyskinesia","volume":"43","author":"Andia","year":"1998","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/BF00428314","article-title":"Normal prolactin responses in tardive dyskinesia","volume":"66","author":"Asnis","year":"1979","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-2007-1017312","article-title":"Tiapride in the treatment of tardive dyskinesia. A double-blind study","volume":"18","author":"Auberger","year":"1985","journal-title":"Pharmacopsychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0035|cit35","unstructured":"Barnes T A prospective study of tardive dyskinesia in the elderly; single-blind comparison of amisulpride and risperidone National Research Register 2002"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0036|cit36","first-page":"475","article-title":"The effect of metoclopramide and haloperidol on tardive dyskinesia","volume":"66","author":"Bateman","year":"1979","journal-title":"British Journal of Pharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD000459.pub3-BIB0037|cit37","first-page":"S141","article-title":"Olanzapine versus clozapine in patients non responsive or intolerant to standard acceptable treatment of schizophrenia","volume":"3","author":"Bitter","year":"2000","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD000459.pub3-BIB0038|cit38","first-page":"1208","article-title":"A strategy to reduce the frequency of early dyskinesias under high-dosed haloperidol treatment","volume":"30","author":"Blaha","year":"1980","journal-title":"Arzneimittel Forschung"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0039|cit39","first-page":"218","article-title":"Atypical and typical neuroleptics and tardive dyskinesia","volume":"23","author":"Borison","year":"1987","journal-title":"Psychopharmacology Bulletin"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0040|cit40","first-page":"118","article-title":"Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia","volume":"17","author":"Branchey","year":"1981","journal-title":"Psychopharmacology Bulletin"},{"issue":"5","key":"10.1002\/14651858.CD000459.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1176\/ajp.138.5.608","article-title":"Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients","volume":"138","author":"Branchey","year":"1981","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0044|cit42","unstructured":"Brecher M Follow-up study of risperidone in the treatment of patients with dementia: interim results on tardive dyskinesia and dyskinesia severity 11th European College of Neuropsychopharmacology Congress (ECNP) Paris European College of Neuropsychopharmacology P4005"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0042|cit43","first-page":"362","article-title":"Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year","volume":"1-3","author":"Brecher","year":"1999","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0043|cit44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00019442-199911001-00115","article-title":"Low frequency of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year","volume":"7","author":"Brecher","year":"1999","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/0006-3223(92)90143-N","article-title":"Clinical predictors of relapse following neuroleptic withdrawal","volume":"32","author":"Buchanan","year":"1992","journal-title":"Biological Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD000459.pub3-BIB0046|cit46","first-page":"289","article-title":"Preliminary observations on the therapeutic action of progabide in tardive dyskinesia","volume":"2","author":"Burner","year":"1989","journal-title":"Brain Dysfunction"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-0404.1982.tb03059.x","article-title":"Tiapride in the treatment of tardive dyskinesia","volume":"65","author":"Buruma","year":"1982","journal-title":"Acta Neurologica Scandinavica"},{"issue":"5","key":"10.1002\/14651858.CD000459.pub3-BIB0048|cit48","first-page":"281","article-title":"A controlled study on the treatment of tardive dyskinesia using 1-stepholidine","volume":"21","author":"Cai","year":"1988","journal-title":"Chinese Journal of Neurology and Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1176\/ajp.136.3.317","article-title":"The trial use of clozapine for abnormal involuntary movement disorders","volume":"136","author":"Caine","year":"1979","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0050|cit50","first-page":"166","article-title":"Pimozide in tardive dyskinesia","volume":"99","author":"Calne","year":"1974","journal-title":"Transcripts of the American Neurology Association"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0051|cit51","first-page":"363","article-title":"Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children","volume":"31","author":"Armenteros","year":"1995","journal-title":"Psychopharmacology Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0052|cit52","first-page":"251","article-title":"Tardive and withdrawal dyskinesia in autistic children: a prospective study","volume":"24","author":"Campbell","year":"1988","journal-title":"Psychopharmacology Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD000459.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/00004583-199706000-00022","article-title":"Neuroleptic-related dyskinesias in autistic children: a prospective longitudinal study","volume":"36","author":"Campbell","year":"1997","journal-title":"Journal of the American Acadamy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0140-6736(80)90107-5","article-title":"Covert dyskinesia in ambulatory schizophrenia","volume":"July","author":"Carpenter","year":"1980","journal-title":"The Lancet"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00426532","article-title":"Pharmacological characterization of tardive dyskinesia","volume":"54","author":"Casey","year":"1977","journal-title":"Psychopharmacology Berlin"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00431993","article-title":"Sulpiride in tardive dyskinesia","volume":"66","author":"Casey","year":"1979","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1001\/archpsyc.1981.01780270044005","article-title":"Effect of des-tyrosine-gamma-endorphin in tardive dyskinesia","volume":"38","author":"Casey","year":"1981","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0058|cit58","first-page":"13","article-title":"Tardive dyskinesia: what is the natural history?","volume":"18","author":"Casey","year":"1983","journal-title":"International Drug Therapy Newsletter"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/0006-3223(92)90035-X","article-title":"GABA agonist-induced changes in motor, oculomotor, and attention measures correlate in schizophrenics with tardive dyskinesia","volume":"32","author":"Cassady","year":"1992","journal-title":"Biological Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD000459.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/j.1552-4604.1978.tb02436.x","article-title":"A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients","volume":"18","author":"Chouinard","year":"1978","journal-title":"Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0061|cit61","first-page":"147","article-title":"Ethopropazine and benztropine in neuroleptic-induced parkinsonism","volume":"40","author":"Chouinard","year":"1979","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00004714-198908000-00003","article-title":"A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia","volume":"9","author":"Chouinard","year":"1989","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"7","key":"10.1002\/14651858.CD000459.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/0278-5846(94)90116-3","article-title":"Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis","volume":"18","author":"Chouinard","year":"1994","journal-title":"Progress in Neuro-psychopharmacology & Biological Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0022-510X(75)90165-3","article-title":"Tardive dyskinesia treated with pimozide","volume":"24","author":"Claveria","year":"1975","journal-title":"Journal of the Neurological Sciences"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD000459.pub3-BIB0065|cit65","first-page":"S24","article-title":"Side effects during long-term treatment with depot antipsychotic medication","volume":"14","author":"Cookson","year":"1991","journal-title":"Clinical Neuropharmacology"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/jcp.0b013e318160864f","article-title":"Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia","volume":"28","author":"Cortese","year":"2008","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/00004714-199706000-00009","article-title":"A treatment for tardive dyskinesia and some other extrapyramidal symptoms","volume":"17","author":"Cowen","year":"1997","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0068|cit68","first-page":"209","article-title":"Tardive dyskinesia in schizophrenic patients treated with psychotropic drugs","volume":"9","author":"Crane","year":"1968","journal-title":"Agressologie"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0069|cit69","first-page":"30","article-title":"Effects of drug withdrawal on tardive dyskinesia","volume":"11","author":"Crane","year":"1969","journal-title":"Activitas Nervosa Superior"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1001\/archneur.1970.00480200082009","article-title":"High doses of trifluperazine and tardive dyskinesia","volume":"22","author":"Crane","year":"1970","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1176\/ajp.130.8.925","article-title":"Management of tardive dyskinesia with thiopropazate","volume":"130","author":"Curran","year":"1973","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0072|cit72","first-page":"469","article-title":"Long term depot maintenance of chronic schizophrenic out patients: the seven year follow up of the Medical Research Council fluphenazine\/placebo trial. II. The incidence of compliance problems, side effects, neurotic symptoms and depression","volume":"146","author":"Curson","year":"1985","journal-title":"British Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD000459.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/1099-1166(200006)15:6<506::AID-GPS146>3.0.CO;2-V","article-title":"A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group","volume":"15","author":"Davidson","year":"2000","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD000459.pub3-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s00406-004-0514-1","article-title":"The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders","volume":"254","author":"Jesus Mari","year":"2004","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"35-6","key":"10.1002\/14651858.CD000459.pub3-BIB0075|cit75","first-page":"1585","article-title":"Controlled therapeutic study of spontaneous bucco-linguo-facial dyskinesias","volume":"55","author":"Delwaide","year":"1979","journal-title":"Semaine des Hopitaux"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0076|cit76","first-page":"900","article-title":"Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia","volume":"22","author":"Diamond","year":"1986","journal-title":"Psychopharmacology Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0920-9964(93)90061-M","article-title":"Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design","volume":"10","author":"Dixon","year":"1993","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0078|cit78","first-page":"267","article-title":"Long term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents","volume":"37","author":"Fahn","year":"1983","journal-title":"Advances in Neurology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0079|cit79","first-page":"19","article-title":"A therapeutic approach to tardive dyskinesia","volume":"46","author":"Fahn","year":"1985","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1192\/bjp.136.5.522b","article-title":"Oxypertine for tardive dyskinesia","volume":"136","author":"Freeman","year":"1980","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0082|cit81","unstructured":"Freeman HL Soni SD Treatment of tardive dyskinesia with oxypertine Supplement to Progress in Neuropsychopharmacology. Proceedings of the 12th Congress of Collegium Internationale Neuro-psychopharmacologicum; 1980 1980 77131327"},{"issue":"5","key":"10.1002\/14651858.CD000459.pub3-BIB0081|cit82","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000468451","article-title":"A controlled trial of oxypertine in tardive dyskinesia","volume":"15","author":"Freeman","year":"1980","journal-title":"International Pharmacopsychiatry"},{"issue":"11","key":"10.1002\/14651858.CD000459.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/archpsyc.1983.01790220020003","article-title":"Anticholinergic challenge and neuroleptic withdrawal. Changes in dyskinesia and symptom measures","volume":"41","author":"Gardos","year":"1984","journal-title":"Archives of General Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/BF00421473","article-title":"Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients","volume":"40","author":"Gerlach","year":"1975","journal-title":"Psychopharmacologia"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/BF00427742","article-title":"Tardive dyskinesia during and following treatment with haloperidol, haloperidol and biperiden, thioridazine and clozapine","volume":"59","author":"Gerlach","year":"1978","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0086|cit86","first-page":"541","article-title":"Dopamine antagonist and agonist treatment of tardive dyskinesia","volume":"24","author":"Bjorndal","year":"1980","journal-title":"Advances in Biochemical Psychopharmacology"},{"issue":"19","key":"10.1002\/14651858.CD000459.pub3-BIB0087|cit87","first-page":"1369","article-title":"Dogmatil in delayed dyskinesia","volume":"61","author":"Gerlach","year":"1985","journal-title":"Semaine des Hopitaux"},{"issue":"S311","key":"10.1002\/14651858.CD000459.pub3-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0447.1984.tb06861.x","article-title":"Sulpiride in tardive dyskinesia","volume":"69","author":"Gerlach","year":"1984","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0089|cit89","article-title":"Primary (initial) and secondary (tardive) dyskinesia: effect of fluperlapine, a new atypical neuroleptic drug","volume-title":"Catecholamines: Neuropharmacology and Central Nervous System - Therapeutic Aspects","author":"Gerlach","year":"1984"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/BF00432029","article-title":"Fluperlapine in tardive dyskinesia and parkinsonism","volume":"84","author":"Korsgaard","year":"1984","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0091|cit91","doi-asserted-by":"crossref","DOI":"10.1007\/978-94-011-6381-1_29","article-title":"Depot fluphenazine and tardive dyskinesia in an outpatient population","volume-title":"Tardive Dyskinesia: Research and Treatment","author":"Gibson","year":"1980"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0092|cit92","article-title":"Effect of drug holidays on tardive dyskinesia","volume-title":"Phenothiazines and structurally related drugs: basic and clinical studies","author":"Gibson","year":"1980"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/archpsyc.1984.01790170097011","article-title":"Tardive dyskinesia: a discontinuation study","volume":"41","author":"Glazer","year":"1984","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/0006-3223(89)90034-6","article-title":"The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia","volume":"26","author":"Glazer","year":"1989","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0095|cit95","first-page":"116","article-title":"The effects of a drug holiday on relapse and tardive dyskinesia in chronic schizophrenics","volume":"17","author":"Goldberg","year":"1981","journal-title":"Psychopharmacology Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00004714-198105000-00005","article-title":"Effects of a six-week drug holiday on symptom status, relapse, and tardive dyskinesia in chronic schizophrenics","volume":"1","author":"Shenoy","year":"1981","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1192\/bjp.145.3.304","article-title":"Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study","volume":"145","author":"Greil","year":"1984","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0098|cit98","first-page":"164","article-title":"Sulpride in tardive dyskinesia","volume":"27","author":"Haggstrom","year":"1980","journal-title":"Current Therapeutic Research"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0099|cit99","first-page":"59","article-title":"Trial of maintenance neuroleptic dose reduction in schizophrenic outpatients: two-year outcome","volume":"54","author":"Heresco-Levy","year":"1993","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0100|cit100","first-page":"268","article-title":"Two-year trial of maintenance neuroleptic dose reduction in schizophrenic out-patients: predictors of relapse","volume":"32","author":"Heresco-Levy","year":"1995","journal-title":"Israel Journal of Psychiatry and Related Science"},{"issue":"554","key":"10.1002\/14651858.CD000459.pub3-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1192\/bjp.120.554.41","article-title":"Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy","volume":"120","author":"Hershon","year":"1972","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1001\/archpsyc.1991.01810280049007","article-title":"Intermittent versus maintenance medication in schizophrenia: two-year results","volume":"48","author":"Herz","year":"1991","journal-title":"Archives of General Psychiatiry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0103|cit103","first-page":"494","article-title":"Drug discontinuation among long term, successfully maintained schizophrenic outpatients","volume":"37","author":"Hogarty","year":"1976","journal-title":"Diseases of the Nervous System"},{"issue":"September","key":"10.1002\/14651858.CD000459.pub3-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archpsyc.1988.01800330021002","article-title":"Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia - results of a two-year controlled study","volume":"45","author":"Hogarty","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0105|cit105","doi-asserted-by":"crossref","unstructured":"Inada T Beasley CM Jr Tanaka Y Walker DJ Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol International Clinical Psychopharmacology 2003 39 48","DOI":"10.1097\/01.yic.0000047781.24295.77"},{"issue":"12","key":"10.1002\/14651858.CD000459.pub3-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1176\/ajp.151.12.1753","article-title":"A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients","volume":"151","author":"Inderbitzin","year":"1994","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0107|cit107","unstructured":"Jean-Noel B Wood AJ Kiesler GM Birkett M Tollefson GD Olanzapine vs. clozapine: an international double blind study in the treatment of resistant schizophrenia 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany 1999 143"},{"issue":"9","key":"10.1002\/14651858.CD000459.pub3-BIB0108|cit108","first-page":"755","article-title":"Masking of tardive dyskinesia with four times-a-day administration of chlorpromazine","volume":"38","author":"Jeste","year":"1977","journal-title":"Diseases of the Nervous System"},{"issue":"May","key":"10.1002\/14651858.CD000459.pub3-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/archpsyc.1979.01780050095012","article-title":"Tardive dyskinesia - reversible and persistent","volume":"36","author":"Jeste","year":"1979","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1600-0447.1983.tb00351.x","article-title":"The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences","volume":"67","author":"Johnson","year":"1983","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1192\/bjp.151.5.634","article-title":"Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia","volume":"151","author":"Johnson","year":"1987","journal-title":"British Journal of Psychiatry"},{"issue":"6679","key":"10.1002\/14651858.CD000459.pub3-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1136\/bmj.298.6679.985","article-title":"Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year","volume":"298","author":"Jolley","year":"1989","journal-title":"BMJ"},{"issue":"6756","key":"10.1002\/14651858.CD000459.pub3-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/bmj.301.6756.837","article-title":"Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years","volume":"301","author":"Jolley","year":"1990","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0114|cit114","first-page":"72","article-title":"Long term treatment of tardive dyskinesia","volume":"40","author":"Jus","year":"1979","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0115|cit115","first-page":"27","article-title":"Persistent tardive dyskinesia in randomly assigned neuroleptic reduction, neuroleptic nonreduction, and no-neuroleptic history groups: preliminary results","volume":"20","author":"Kalachnik","year":"1984","journal-title":"Psychopharmacology Bulletin"},{"issue":"9","key":"10.1002\/14651858.CD000459.pub3-BIB0116|cit116","first-page":"327","article-title":"Does clozapine cause tardive dyskinesia?","volume":"54","author":"Kane","year":"1993","journal-title":"Journal of Clinical Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD000459.pub3-BIB0117|cit117","first-page":"S165","article-title":"Olanzapine improves tardive dyskinesia in patients with schizophrenia in a controlled prospective study","volume":"5","author":"Kinon","year":"2002","journal-title":"International Journal of Neuropsychopharmacology. Abstracts of the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum"},{"issue":"6","key":"10.1002\/14651858.CD000459.pub3-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.pnpbp.2004.05.016","article-title":"Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods","volume":"28","author":"Kinon","year":"2004","journal-title":"Progress in neuro-psychopharmacology & biological psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0119|cit119","unstructured":"Kinon BJ Stauffer VL Wang L Thi K Niewoehner J Kollack-Walker S Olanzapine improves dyskinesia in patients with schizophrenia International Congress on Schizophrenia Research (ICSR) March 29-April 2, 2003, Colorado Springs, Colorado 2003"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0120|cit120","unstructured":"Kinon BJ Stauffer VL Wang L Thi KT Olanzapine improves tardive dyskinesia in patients with schizophrenia 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"issue":"3 Suppl.1","key":"10.1002\/14651858.CD000459.pub3-BIB0121|cit121","first-page":"191","article-title":"Olanzapine improves tardive dyskinesia in patients with schizophrenia","volume":"53","author":"Kinon","year":"2002","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0920-9964(03)80175-5","article-title":"Olanzapine improves tardive dyskinesia in patients with schizophrenia","volume":"60","author":"Kollack-Walker","year":"2003","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0165-1781(83)90046-X","article-title":"Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal","volume":"9","author":"Kirch","year":"1983","journal-title":"Psychiatry Research"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0124|cit124","first-page":"187","article-title":"Extra-pyramidal signs and symptoms (EPS) in recent onset schizophrenia: a comparison of risperidone and haloperidol","volume":"67","author":"Kopala","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"9","key":"10.1002\/14651858.CD000459.pub3-BIB0125|cit125","first-page":"990","article-title":"Comparison of thiopropazate and trifluoperazine on oral dyskinesia - a double blind study","volume":"16","author":"Lal","year":"1974","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1177\/070674379403900406","article-title":"Effects of neuroleptic reduction in schizophrenic outpatients receiving high doses","volume":"39","author":"Leblanc","year":"1994","journal-title":"Canadian Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD000459.pub3-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00002826-198710000-00009","article-title":"Treatment of permanent tardive dyskinesia with tiapride, a selective D2-receptor blocking agent","volume":"10","author":"Leblhuber","year":"1987","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0128|cit128","first-page":"483","article-title":"Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study","volume":"24","author":"Levine","year":"1980","journal-title":"Advances in Biochemical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00004714-198808000-00004","article-title":"Pharmacologic characterization of tardive dyskinesia","volume":"8","author":"Lieberman","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.158.4.503","article-title":"The effects of clozapine on tardive dyskinesia","volume":"158","author":"Lieberman","year":"1991","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0131|cit131","first-page":"57","article-title":"Clozapine effects on tardive dyskinesia","volume":"25","author":"Lieberman","year":"1989","journal-title":"Psychopharmacology Bulletin"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD000459.pub3-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"S410","DOI":"10.1016\/S0924-977X(06)70513-2","article-title":"Remission of tardive dyskinesia following the switch from clozapine to zotepine: 2-year follow-up","volume":"16","author":"Lin","year":"2006","journal-title":"European Neuropsychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD000459.pub3-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3928\/0279-3695-19930901-07","article-title":"The effect of clozapine - on preexisting tardive dyskinesia","volume":"31","author":"Littrell","year":"1993","journal-title":"Journal of Psychosocial Nursing and Mental Health Services"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1017\/S0033291700047498","article-title":"Failure of lithium treatment in established tardive dyskinesia","volume":"10","author":"MacKay","year":"1980","journal-title":"Psychological Medicine"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archpsyc.1987.01800180028005","article-title":"Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome","volume":"44","author":"Marder","year":"1987","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/archpsyc.1983.01790220015002","article-title":"Costs and benefits of two doses of fluphenazine","volume":"41","author":"Marder","year":"1984","journal-title":"Archives of General Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD000459.pub3-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1192\/bjp.137.6.510","article-title":"Intermittent pimozide versus fluphenazine decanoate as maintenance therapy in chronic schizophrenia","volume":"137","author":"McCreadie","year":"1980","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD000459.pub3-BIB0138|cit138","first-page":"876","article-title":"Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. A single-blind crossover study versus placebo","volume":"46","author":"Meco","year":"1989","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/npp.1994.31","article-title":"Effect of antipsychotic withdrawal on negative symptoms in schizophrenia","volume":"11","author":"Miller","year":"1994","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0140|cit140","first-page":"227","article-title":"Tardive dyskinesia: pathophysiological mechanisms and clinical trials","volume":"XIV","author":"Gerlach","year":"1988","journal-title":"L'Encephale"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0141|cit141","first-page":"423","article-title":"Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicenter study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden","volume":"90","author":"Nordic Dyskinesia Study Group","year":"1986","journal-title":"Psychopharmacology"},{"issue":"25","key":"10.1002\/14651858.CD000459.pub3-BIB0142|cit142","first-page":"1682","volume":"149","author":"Povlsen","year":"1987","journal-title":"Ugeskr Laeger"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0143|cit143","first-page":"101","article-title":"Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease","volume":"28","author":"Newcomer","year":"1992","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0144|cit144","first-page":"132","article-title":"Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients","volume":"50","author":"Newton","year":"1989","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0145|cit145","first-page":"195","article-title":"Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients","volume":"43","author":"Odejide","year":"1982","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0146|cit146","unstructured":"Pai Y-M Yu S-C Lin C-C Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, PA, USA 2002"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0147|cit147","unstructured":"Pai YM Yu SC Lin CC Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study Annual Meeting of the American Psychiatric Association; 2001 May 5-10; LA, USA Marathon Multimedia 2001 96173072"},{"issue":"10","key":"10.1002\/14651858.CD000459.pub3-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/000992287501401013","article-title":"Tardive dyskinesia as a possible sequel of long-term therapy with phenothiazines","volume":"14","author":"Paulson","year":"1975","journal-title":"Clinical Pediatrics"},{"issue":"1-2","key":"10.1002\/14651858.CD000459.pub3-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/BF02245620","article-title":"Clozapine versus typical antipsychotics. A retro- and prospective study of extrapyramidal side effects","volume":"124","author":"Peacock","year":"1996","journal-title":"Psychopharmacologia"},{"issue":"5","key":"10.1002\/14651858.CD000459.pub3-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1192\/bjp.bp.111.101485","article-title":"Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs","volume":"200","author":"Peluso","year":"2012","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004583-198901000-00016","article-title":"Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration","volume":"28","author":"Perry","year":"1989","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0152|cit152","first-page":"140","article-title":"Neuroleptic-related dyskinesias in autistic children: a prospective study","volume":"21","author":"Perry","year":"1985","journal-title":"Psychopharmacology Bulletin"},{"issue":"12","key":"10.1002\/14651858.CD000459.pub3-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1176\/ajp.138.12.1620","article-title":"Neuroleptic-free intervals in the treatment of schizophrenia","volume":"138","author":"Pyke","year":"1981","journal-title":"American Journal of Psychiatry"},{"issue":"8","key":"10.1002\/14651858.CD000459.pub3-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/jnnp.47.8.844","article-title":"A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia","volume":"47","author":"Quinn","year":"1984","journal-title":"Journal of Neurology Neurosurgery and Psychiatry"},{"issue":"19","key":"10.1002\/14651858.CD000459.pub3-BIB0155|cit155","first-page":"1376","article-title":"Double blind trial of Dogmatil in Huntington chorea and tardive dyskinesia","volume":"61","author":"Quinn","year":"1985","journal-title":"Semaine des Hopitaux"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1176\/ajp.134.1.84","article-title":"Tardive dyskinesia: are first signs reversible?","volume":"134","author":"Quitkin","year":"1977","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0157|cit157","unstructured":"Rapoport J Kumra S Jacobsen LK The spectrum of extrapyramidal symptoms in children and young adults 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, USA 1997"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1055\/s-0028-1094589","article-title":"Dopamine-receptor stimulators and neuroleptic-induced dyskinesia","volume":"11","author":"Ringwald","year":"1978","journal-title":"Pharmakopsychiatrie und Neuropsychopharmakologie"},{"issue":"20","key":"10.1002\/14651858.CD000459.pub3-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1001\/jama.290.20.2693","article-title":"Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial","volume":"290","author":"Rosenheck","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1192\/bjp.116.532.277","article-title":"Treatment of persistent phenothiazine-induced oral dyskinesia","volume":"116","author":"Roxburgh","year":"1970","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0006-3223(95)00082-8","article-title":"Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation","volume":"38","author":"Schultz","year":"1995","journal-title":"Biological Psychiatry"},{"issue":"9","key":"10.1002\/14651858.CD000459.pub3-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/jnnp.53.9.800","article-title":"Sulpiride in tardive dyskinesia","volume":"53","author":"Schwartz","year":"1990","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0010-440X(81)90069-9","article-title":"Tardive dyskinesia: two-year recovery","volume":"22","author":"Seeman","year":"1981","journal-title":"Comprehensive Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/BF00571412","article-title":"Clozapine in tardive dyskinesia","volume":"56","author":"Simpson","year":"1978","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0165|cit165","unstructured":"Singer K Cheng MN Thiopropazate hydrochloride (Dartalan) in persistent dyskinesia with phenothiazine therapy 5th World Congress of Psychiatry; 1971 Nov 28 - Dec 4; Ciudad de Mexico, Mexico 1971 528 79081577"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/bmj.4.5778.22","article-title":"Thiopropazate hydrochloride in persistent dyskinesia","volume":"4","author":"Singer","year":"1971","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0167|cit167","first-page":"319","article-title":"Neuroleptic withdrawal in patients meeting criteria for supersensitivity psychosis","volume":"51","author":"Singh","year":"1990","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0168|cit168","first-page":"263","article-title":"Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis","volume":"48","author":"Small","year":"1987","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD000459.pub3-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/jnnp.42.6.576","article-title":"Six month evaluation of thiopropazate hydrochloride in tardive dyskinesia","volume":"42","author":"Smith","year":"1979","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1192\/bjp.144.1.48","article-title":"Oxypertine in tardive dyskinesia: an 8-week controlled study","volume":"144","author":"Soni","year":"1984","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0920-9964(92)90126-P","article-title":"A one-year dose reduction study in chronic schizophrenic inpatients: amisulpride vs haloperidol","volume":"6","author":"Barnes","year":"1992","journal-title":"Schizophrenia Research"},{"issue":"December","key":"10.1002\/14651858.CD000459.pub3-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1192\/bjp.171.6.564","article-title":"One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol","volume":"171","author":"Speller","year":"1997","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4088\/JCP.v58n0706","article-title":"Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients","volume":"58","author":"Spivak","year":"1997","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/archpsyc.1988.01800330059007","article-title":"The effect of neuroleptics and tardive dyskinesia on smooth-pursuit eye movement in chronic schizophrenia","volume":"45","author":"Spohn","year":"1988","journal-title":"Archives of General Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/brcg.1993.1042","article-title":"The effect of attention\/information processing impairment of tardive dyskinesia and neuroleptics in chronic schizophrenics. Special Issue: tardive dyskinesia and cognitive dysfunction","volume":"23","author":"Spohn","year":"1993","journal-title":"Brain and Cognition"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00019442-200409000-00009","article-title":"A randomized, double-blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances","volume":"12","author":"Suh","year":"2004","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1532-5415.1994.tb01752.x","article-title":"Effects of antipsychotic withdrawal in elderly nursing home residents","volume":"42","author":"Thapa","year":"1994","journal-title":"Journal of the American Geriatrics Society"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1192\/bjp.174.1.23","article-title":"A randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol","volume":"174","author":"Beasley","year":"1999","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0920-9964(97)88754-3","article-title":"What is the differential risk of tardive dyskinesia with the novel antipsychotic olanzapine?","volume":"29","author":"Tamura","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1176\/ajp.154.9.1248","article-title":"Blind, controlled, long term study of the comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol","volume":"154","author":"Tollefson","year":"1997","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0181|cit181","doi-asserted-by":"crossref","unstructured":"Tran PV Dellva MA Tollefson GD Beasley CMJr Potvin JH Kiesler GM Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia Journal of clinical psychiatry 1997 205 11","DOI":"10.4088\/JCP.v58n0505"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1192\/bjp.121.6.605","article-title":"Tardive dyskinesia: its relation to neuroleptic and antiparkinson drugs","volume":"121","author":"Turek","year":"1972","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0183|cit183","first-page":"A47","article-title":"Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent","volume":"9","author":"Williamson","year":"1995","journal-title":"Journal of Psychopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD000459.pub3-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1176\/ajp.156.9.1374","article-title":"Risperidone in treatment-refractory schizophrenia","volume":"156","author":"Wirshing","year":"1999","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00427950","article-title":"A depot neuroleptic withdrawal study neurological effects","volume":"80","author":"Wistedt","year":"1983","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0186|cit186","first-page":"255","volume":"17","author":"Wolf","year":"1991","journal-title":"Encephale"},{"issue":"1-2","key":"10.1002\/14651858.CD000459.pub3-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0920-9964(97)88829-9","article-title":"A blinded, controlled, long-term study of the comparative incidence of treatement-emergent tardive dyskinesia with olanzapine or haloperidol","volume":"29","author":"Wright","year":"1998","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00431099","article-title":"Long-term neuroleptic treatment of chronic schizophrenic patients: clinical and biochemical effects of withdrawal","volume":"73","author":"Zander","year":"1981","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD000459.pub3-BIB0189|cit189","first-page":"374","article-title":"Sulpiride in tardive dyskinesia","volume":"78","author":"Zarebinski","year":"1990","journal-title":"South African Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0190|cit190","first-page":"183","article-title":"A double-blind trial of flunarizine therapy for tardive dyskinesia","volume":"3","author":"Zeng","year":"1994","journal-title":"Chinese Journal of Pharmaco Epidemiology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0191|cit191","unstructured":"N0546099389 A six month, rater blind comparison of quetiapine and risperidone in the treatment of tardive dyskinesia in patients with schizophrenia National Research Register"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0192|cit192","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000203.pub3","article-title":"Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia","author":"Alabed","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7066","key":"10.1002\/14651858.CD000459.pub3-BIB0193|cit193","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0194|cit194","unstructured":"American Psychiatry Association Tardive dyskinesia: a task force report of the American Psychiatric Association Washington DC 1992"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0195|cit195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1991.tb05604.x","article-title":"Should we cross off the crossover?","volume":"32","author":"Armitage","year":"1991","journal-title":"Journal of Clinical Pharmacology"},{"issue":"10","key":"10.1002\/14651858.CD000459.pub3-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.4088\/JCP.v69n1008","article-title":"Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study","volume":"69","author":"Ascher-Svanum","year":"2008","journal-title":"Journal of Clinical Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0197|cit197","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00004714-200004000-00011","article-title":"Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies","volume":"20","author":"Ballesteros","year":"2000","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"Westminster Medical School HHES. A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0199|cit199","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-079035-7.50021-X","article-title":"The side-effects of antipsychotic drugs. I. CNS and neuromuscular effects","volume-title":"Antipsychotic drugs and their side-effects","author":"Barnes","year":"1993"},{"issue":"8","key":"10.1002\/14651858.CD000459.pub3-BIB0200|cit200","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1192\/bjp.144.5.498","article-title":"Tardive dyskinesia: fluctuating patient or fluctuating rater","volume":"144","author":"Bergen","year":"1984","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0202|cit202","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1192\/bjp.154.4.523","article-title":"The course of tardive dyskinesia in patients on long-term neuroleptics","volume":"154","author":"Bergen","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/0006-3223(92)90071-7","article-title":"Predictors of the course of tardive dyskinesia in patients receiving neuroleptics","volume":"32","author":"Bergin","year":"1992","journal-title":"Biological Psychiatry"},{"issue":"43","key":"10.1002\/14651858.CD000459.pub3-BIB0204|cit204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21430","article-title":"Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia","volume":"21","author":"Bergman","year":"2017 Aug","journal-title":"Health Technol Assess"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0205|cit205","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000205.pub2","article-title":"Benzodiazepines for neuroleptic-induced tardive dyskinesia","author":"Bhoopathi","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0206|cit206","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0207|cit207","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0208|cit208","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1749-6632.1989.tb14918.x","article-title":"Possible involvement of free radical in neuroleptic-induced movement disorders","volume":"570","author":"Cadet","year":"1989","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0209|cit209","article-title":"Tardive dyskinesia: what is the long-term outcome?","volume-title":"Tardive dyskinesia and neuroleptics: from dogma to reason","author":"Casey","year":"1986"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0210|cit210","article-title":"Tardive dyskinesia: pathophysiology","volume-title":"Psychopharmacology. The Fourth Generation of Progress","author":"Casey","year":"1994"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0211|cit211","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0920-9964(98)00160-1","article-title":"Tardive dyskinesia and atypical antipsychotic drugs","volume":"35","author":"Casey","year":"1999","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0212|cit212","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/npp.1993.26","article-title":"Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence","volume":"8","author":"Cavallaro","year":"1993","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/JCP.0b013e3181929f94","article-title":"Mortality rates among patients with schizophrenia and tardive dyskinesia","volume":"29","author":"Chong","year":"2009","journal-title":"Journal of Clinoca; Psychopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD000459.pub3-BIB0214|cit214","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0215|cit215","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","author":"Chouinard","year":"2008","journal-title":"Psychotherapy and Psychosomatics"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0216|cit216","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13311-013-0222-5","article-title":"Tardive dyskinesia: therapeutic options for an increasingly common disorder","volume":"11","author":"Cloud","year":"2014","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0217|cit217","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","author":"Correll","year":"2004","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0218|cit218","unstructured":"Veritas Health Innovation Covidence systematic review software"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0219|cit219","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0220|cit220","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD000459.pub3-BIB0221|cit221","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0223|cit223","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0224|cit224","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000458.pub2","article-title":"Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0225|cit225","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD000459.pub3-BIB0226|cit226","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000206.pub3","article-title":"Calcium channel blockers for neuroleptic-induced tardive dyskinesia","author":"Essali","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"suppl 4","key":"10.1002\/14651858.CD000459.pub3-BIB0227|cit227","first-page":"10","article-title":"Prevalence of spontaneous dyskinesia in schizophrenia","volume":"61","author":"Fenton","year":"2000","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0228|cit228","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.56.6.805","article-title":"The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up","volume":"56","author":"Fernandez","year":"2001","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0229|cit229","article-title":"The crossover study","volume-title":"The Design and Analysis of Clinical Experiments","author":"Fleiss","year":"1984"},{"issue":"7","key":"10.1002\/14651858.CD000459.pub3-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0231|cit231","doi-asserted-by":"crossref","first-page":"31S","DOI":"10.1097\/00004714-198808001-00007","article-title":"The natural history of tardive dyskinesia","volume":"8","author":"Gardos","year":"1988","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1176\/ajp.151.6.836","article-title":"Ten-year outcome of tardive dyskinesia","volume":"151","author":"Gardos","year":"1994","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1600-0447.1988.tb05138.x","article-title":"Tardive dyskinesia","volume":"77","author":"Gerlach","year":"1988","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1600-0447.1993.tb03366.x","article-title":"The St. Hans Rating Scale for extrapyramidal syndromes: reliability and validity","volume":"87","author":"Gerlach","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpsyc.1995.03950150005001","article-title":"Neuroleptic withdrawal in schizophrenic patients - a review of the literature","volume":"52","author":"Gilbert","year":"1995","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0236|cit236","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1192\/bjp.157.4.585","article-title":"Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication","volume":"157","author":"Glazer","year":"1990","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0238|cit238","article-title":"Manual for the ECDEU Assessment Battery","volume-title":"National Institute of Mental Health. In: Guy W, Bonato RR, editor(s)","author":"Guy","year":"1970"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0239|cit239","volume-title":"ECDEU Assessment Manual for Psychopharmacology. Revised Edition","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0241|cit241","article-title":"Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]","volume-title":"The Cochrane Library","author":"Higgins","year":"2005"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0242|cit242","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 (updated September 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0243|cit243","unstructured":"Higgins JPT Deeks JJ (editors) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0244|cit244","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0245|cit245","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0246|cit246","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/schbul\/19.2.303","article-title":"Tardive dyskinesia","volume":"19","author":"Jeste","year":"1993","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0248|cit248","article-title":"Do low-dose neuroleptics prevent or ameliorate tardive dyskinesia?","volume-title":"Tardive Dyskinesia and Neuroleptics: From Dogma to Reason","author":"Kane","year":"1986"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0249|cit249","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"11","key":"10.1002\/14651858.CD000459.pub3-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD000459.pub3-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"10","key":"10.1002\/14651858.CD000459.pub3-BIB0253|cit253","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1017\/S0033291709005455","article-title":"Second-generation antipsychotics for schizophrenia: can we resolve the conflict?","volume":"39","author":"Leucht","year":"2009","journal-title":"Psychological Medicine"},{"issue":"Supplement 29","key":"10.1002\/14651858.CD000459.pub3-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1192\/S0007125000298255","article-title":"Introduction","volume":"168","author":"Lieberman","year":"1996","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0255|cit255","doi-asserted-by":"crossref","first-page":"Suppl. 334","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"76","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"5 Suppl B","key":"10.1002\/14651858.CD000459.pub3-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.18553\/jmcp.2012.18.S5-B.1","article-title":"Summary of the comparative effectiveness review on off-label use of atypical antipsychotics","volume":"18","author":"Maher","year":"2012","journal-title":"Journal of Managed Care Pharmacy"},{"issue":"9","key":"10.1002\/14651858.CD000459.pub3-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/070674370505000907","article-title":"Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 1: pathophysiology and mechanisms of induction","volume":"50","author":"Margolese","year":"2005","journal-title":"Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0259|cit259","first-page":"44","article-title":"Prevalence of tardive dyskinesia and all-cause mortality amongst patients in a large psychiatric institute in Rio de Janeiro","volume":"38","author":"Martins","year":"2011","journal-title":"Revista de Psiquiatria Cl\u00ednica"},{"issue":"12","key":"10.1002\/14651858.CD000459.pub3-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.4088\/JCP.v68n1210","article-title":"Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis","volume":"68","author":"Miller","year":"2007","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1192\/bjp.bp.108.050088","article-title":"Extrapyramidal side-effects of antipsychotics in a randomised trial","volume":"193","author":"Miller","year":"2008","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0262|cit262","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","article-title":"The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"7","author":"Moher","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/archpsyc.1993.01820210057007","article-title":"Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medication. Results of the Yale Tardive Dyskinesia Study","volume":"50","author":"Morgenstern","year":"1993","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0264|cit264","unstructured":"NICE Psychosis and schizophrenia in adults: treatment and management NICE clinical guideline 178 (guidance.nice.org.uk\/cg178) 2014"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0266|cit266","article-title":"Crossover trials","volume-title":"Clinical trials. A practical approach","author":"Pocock","year":"1983"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1192\/bjp.bp.106.035063","article-title":"Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics","volume":"191","author":"Rosenheck","year":"2007","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1017\/S0924933800002625","article-title":"Treatment of tardive dyskinesias with vitamin E","volume":"6","author":"Schmidt","year":"1991","journal-title":"European Psychiatry"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0269|cit269","first-page":"431","article-title":"Clinical research for the treatment of schizophrenia","volume":"29","author":"Schooler","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0270|cit270","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD000459.pub3-BIB0271|cit271","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2165\/00003495-199652060-00006","article-title":"Pharmacological options for the management of dyskinesias","volume":"52","author":"Shale","year":"1996","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0272|cit272","first-page":"InPress","article-title":"Study-based registers of randomized controlled trials: starting a systematic review with data extraction or meta-analysis","volume":"InPress","author":"Shokraneh","year":"2017","journal-title":"BioImpacts"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archpsyc.1980.01780250054006","article-title":"Changes in prevalence, severity and recovery in tardive dyskinesia with age","volume":"37","author":"Smith","year":"1980","journal-title":"Archives of General Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0275|cit275","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000204","article-title":"Anticholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Soares","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0276|cit276","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000204","article-title":"Anticholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"1997","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0277|cit277","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000208","article-title":"Miscellaneous treatments for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0278|cit278","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000209.pub2","article-title":"Vitamin E for neuroleptic-induced tardive dyskinesia","author":"Soares-Weiser","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD000459.pub3-BIB0279|cit279","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000207","article-title":"Cholinergic medication for neuroleptic-induced tardive dyskinesia","author":"Tammenmaa","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0280|cit280","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/B978-0-444-52014-2.00043-4","article-title":"Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs","volume":"100","author":"Tarsy","year":"2011","journal-title":"Handbook of Clinical Neurology"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0281|cit281","doi-asserted-by":"crossref","DOI":"10.3109\/9780203092835","volume-title":"The Maudsley Prescribing Guidelines (10th Edition)","author":"Taylor","year":"2009"},{"issue":"5","key":"10.1002\/14651858.CD000459.pub3-BIB0282|cit282","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD000459.pub3-BIB0283|cit283","article-title":"Abnormal involuntary movements and psychosis in the preneuroleptic era and in unmedicated patients: implications for the concept of tardive dyskinesia","volume-title":"Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects","author":"Waddington","year":"1988"},{"issue":"4","key":"10.1002\/14651858.CD000459.pub3-BIB0284|cit284","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4088\/JCP.07m03890yel","article-title":"Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study","volume":"71","author":"Woods","year":"2010","journal-title":"Journal of Clinical Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD000459.pub3-BIB0285|cit285","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0286|cit286","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000459","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia","author":"McGrath","year":"1998","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD000459.pub3-BIB0287|cit287","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000459.pub2","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia","author":"McGrath","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD000459.pub3-BIB0288|cit288","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000459.pub2","article-title":"Neuroleptic reduction and\/or cessation and neuroleptics as specific treatments for tardive dyskinesia","author":"Soares-Weiser","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD000459.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T01:44:02Z","timestamp":1751334242000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD000459.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":288,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd000459.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]}}}